Measuring our impact

Understanding and measuring our impact is a central part of ILEP’s work towards achieving a world without leprosy.

We need to collect and analyse a range of data to understand the impact our work is having for individuals, families, communities and countries around the world. This evidence helps us determine what is working well, where fresh approaches are needed and which areas need more investment and support.

In short, it gives us a clearer picture of leprosy across the world and helps us focus our efforts more effectively.

That’s why improving our collective efforts on Monitoring and Evaluation (M&E) is vital if we are to achieve our ambitious goals for Zero Transmission, Zero Disabilities and Zero Discrimination.

An ILEP M&E group has been formed to improve what we are measuring and how we are measuring it. This is important so we can understand and demonstrate the collective impact of ILEP, and see where progress is being made and where the gaps are.  The group will also review where we are getting our data from and how data is collected by our country programmes, so relevant and accurate information can be shared with the London Declaration Scorecard, in coordination with the WHO.

Our top 3 indicators are:

  • The number of new cases in children, per million children (Zero Transmission)
  • The number of new cases with visible disabilities (G2D), per million population (Zero Disabilities)
  • The number of countries with legislation allowing discrimination on the basis of leprosy (Zero Discrimination)

There are many more indicators that break down the data further, such as:

  • Number of countries that have implemented examination of contacts of new leprosy cases
  • Average completion rate of MDT in all cases
  • Number of boys and girls diagnosed with G2D (disaggregation by sex)
  • Number of countries that have data available on the number of cured patients presenting with new disabilities not present at the end of treatment
  • Number of countries where sub-district level / district level / provincial or state level mapping of leprosy case detection is implemented
  • Number of countries that assess the level of stigma in the community and among patients and healthcare workers

We gather this information via our members every year, and publish the results. Find out more about the ILEP country survey and analysis.

Download our country data for 2016 here